The latest study results show that the survival time of patients with untreated colorectal cancer liver metastases is only 6.9 months, while the median survival time of patients with complete resection of liver metastases is 35 months, and the 5-year survival rate can reach 30%-50%. Therefore, the choice of treatment modality for patients with colorectal cancer liver metastases has an important significance on their prognosis. At present, the treatment of colorectal cancer liver metastases is still mainly based on surgical treatment, with multiple treatments as an adjuvant comprehensive treatment. The resection of liver metastases is still the only effective method to cure colorectal cancer liver metastases. Therefore, patients who meet the indications for surgery are recommended to undergo surgery at the appropriate time; if the initial liver metastases are unresectable, patients can choose to undergo neoadjuvant chemotherapy, and then select the appropriate time for surgery when the metastases are transformed into resectable liver cancer. The indications for resection of liver metastases usually include: 1. The primary site of colorectal cancer can be or has been resected radically. 2. Radical resection of liver metastases is feasible according to the anatomical basis of the liver and the scope of the lesion, and sufficient liver function is required to be preserved, with the remaining liver volume ≥ 50% when the primary colorectal lesion and liver metastases are removed simultaneously, and ≥ 30% when the primary lesion and liver metastases are removed in two operations. 3. The patient’s general condition allows, and there is no unresectable extrahepatic metastases. If liver metastases are found at the time of colorectal cancer diagnosis, when the liver metastases are small and mostly located in the periphery or confined to half of the liver, and the expected remaining liver volume is ≥50%, simultaneous resection of the primary and metastases is recommended. When simultaneous resection is not met, the primary and liver metastases can also be resected in stages, that is, the primary colorectal cancer foci are surgically removed first, and then the liver metastases are resected in stages, and the timing is chosen 4-6 weeks after the radical resection of colorectal cancer. For liver metastases found after radical resection of colorectal primary foci, there is no recurrence of colorectal primary foci, liver metastases can be completely resected and the remaining liver volume is ≥ 30% (patients without cirrhosis), liver metastases can be surgically resected. In addition, some doctors will choose preoperative neoadjuvant chemotherapy for resectable colorectal cancer liver metastases to reduce the tumor load and decrease postoperative recurrence. For patients with liver metastases found at the time of colorectal cancer diagnosis, neoadjuvant therapy can be considered when there is no bleeding, obstruction or perforation at the primary site. It can also be combined with molecular targeted therapy. However, for patients who have received chemotherapy within 12 months before the discovery of liver metastases, the role of preoperative neoadjuvant chemotherapy is limited, and direct resection of liver metastases should be considered, followed by postoperative adjuvant therapy. For unresectable colorectal cancer liver metastases, comprehensive treatment is the main treatment, including systemic chemotherapy, interventional chemotherapy, molecular targeted therapy and local treatment for liver metastases such as radiofrequency ablation, anhydrous alcohol injection and radiotherapy, etc. The choice of treatment plan should be based on the patient’s condition and discussed by the multidisciplinary team. Some of the liver metastases that cannot be resected at the initial diagnosis can be converted to be suitable for surgical resection after systematic and comprehensive treatment, and their postoperative survival rates are similar to those of patients with resectable liver metastases undergoing surgical resection.